Completed paediatric studies: submission, processing and assessment

AI Summary

This guidance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) outlines mandatory requirements for Marketing Authorisation Holders (MAHs) regarding the submission of paediatric study results. Governed by the Human Medicines Regulations 2012, the framework mandates that any study involving participants under the age of 18 must be reported to the MHRA within six months of completion. This requirement applies to all UK marketing authorisations, regardless of whether the study was part of a formal Paediatric Investigation Plan or if the MAH intends to seek a paediatric indication. To comply, companies must submit a standardized cover letter detailing whether the study necessitates urgent safety or efficacy updates to the product information. If the results are being evaluated by a non-UK regulator, such as the European Medicines Agency, the MAH must provide the final assessment report to the MHRA as soon as it becomes available. Following an initial appraisal, the MHRA may determine that no further action is needed, or they may require a full assessment. If a full assessment is necessary to update the product information, the MAH is required to submit a Type II variation application within 60 days. These procedures ensure that all clinical data relevant to the paediatric population is promptly reviewed to protect public health, with specific considerations for the new UK-wide licensing measures effective from January 2025.